Outrageous Stock: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Y-mAbs Therapeutics, Inc. (YMAB) recently specified financial results for the second quarter of 2019.

On Thursday, Y-mAbs Rehabs, Inc. (NASDAQ: YMAB) shares rate traded in between $26.38 and $27.11 during the last trading session above/below with +1.29% at $26.63. The shares recorded trading volume 103,794 shares as compared to its typical volume of 169,934 shares.

Second Quarter 2019 Financial Results

For the 6 months ended June 30, 2019, Y-mAbs mentioned a bottom line of $34.0 M, or $0.99 per diluted and basic share, contrast to a bottom line of $17.8 M, or $0.66 per fundamental and diluted share, mentioned for the 6 months ended June 30, 2018.

Y-mAbs stated a bottom line of $18.0 M, or $0.53 per diluted and standard share, for the 3 months ended June 30, 2019, contrast to a bottom line of $10.3 M, or $0.39 per fundamental and diluted share, for the 3 months ended June 30, 2018.

Running Expenses

Research study and Development
Research study and advancement expenses were $14.5 M for the three months ended June 30, 2019, contrast to $8.3 M for the three months ended June 30, 2018, a raise of $6.2 M. The boost in research study and development expenditures mainly shows the following:

$ 2.9 M boost in outsourced production for our 2 lead item candidates, naxitamab and omburtamab;
$ 2.2 M increase in outsourced research and materials to support expanding development activities; and
$ 0.7 M boost in personnel costs.

Research study and advancement expenditures were $27.0 M for the 6 months ended June 30, 2019, contrast to $14.5 M for the six months ended June 30, 2018, a raise of $12.5 M. The increase in research study and development expenses mostly reflects the following:

$ 7.2 M boost in outsourced manufacturing for our two lead item candidates, naxitamab and omburtamab;
$ 3.5 M boost in outsourced research and products to support broadening development activities; and
$ 1.4 M boost in workers expenses.

Money and Cash Equivalents
The Company had about $120.2 M in money and money equivalents as of June 30, 2019, contrast to $147.8 M as of December 31, 2018. The decline of $27.6 M was primarily attributable to the increased costs of operation as the Company prepares for its submission of rolling BLAs for naxitamab and omburtamab and the accumulation of the Companys industrial facilities.

The corporation holds 34.81 million exceptional shares and its 17.58 million shares were drifted in the market. YMAB price volatility for a month kept in mind as 5.58% nevertheless its rate volatility for a week recorded as 4.21%. The stock established an unfavorable trend of -0.86% in last week and showed rise of 20.83% in previous month.